Xikun Han1,2, Emmanuelle Souzeau3, Jue-Sheng Ong1,2, Jiyuan An1, Owen M Siggs3, Kathryn P Burdon3,4, Stephen Best5, Ivan Goldberg6, Paul R Healey6,7, Stuart L Graham6,8, Jonathan B Ruddle9,10,11, Richard A Mills3, John Landers3, Anna Galanopoulos12, Andrew J R White7, Robert Casson12, David A Mackey4,13, Alex W Hewitt4,9, Puya Gharahkhani1, Jamie E Craig3, Stuart MacGregor1. 1. Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. 2. School of Medicine, University of Queensland, St Lucia, Brisbane, Australia. 3. Department of Ophthalmology, Flinders University, Flinders Medical Centre, Adelaide, Australia. 4. Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia. 5. Eye Department, Greenlane Clinical Centre, Auckland District Health Board, Auckland, New Zealand. 6. Discipline of Ophthalmology, Sydney Eye Hospital, University of Sydney, Sydney, Australia. 7. Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, Australia. 8. Ophthalmology and Vision Science, Faculty of Medicine and Human Sciences, Macquarie University, Australia. 9. Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia. 10. Ophthalmology, University of Melbourne, Department of Surgery, Melbourne, Australia. 11. Department of Ophthalmology, Royal Children's Hospital, Melbourne, Australia. 12. South Australian Institute of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, Adelaide, Australia. 13. Centre for Ophthalmology and Visual Sciences, Lions Eye Institute, University of Western Australia, Perth, Australia.
Abstract
Importance: The p.Gln368Ter (rs74315329) risk allele in the myocilin gene (MYOC) was initially reported to have high penetrance in glaucoma registry-based studies, but much lower estimates were recently obtained from population-based studies. We investigated this disparity using data from Australia and the United Kingdom. Objectives: To examine the penetrance and effect size of the MYOC p.Gln368Ter variant with glaucoma and ocular hypertension (OHT). Design, Setting, and Participants: This cross-sectional study within the UK Biobank (UKBB) included participants of white British ancestry. Glaucoma cases were defined by International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) diagnoses and self-reported questionnaires. Carriers of the MYOC p.Gln368Ter variant were identified using genotype imputation from arrays. In contrast, 2 Australian registry-based studies, the Australian and New Zealand Registry of Advanced Glaucoma and the Glaucoma Inheritance Study in Tasmania, ascertained glaucoma cases referred by eye care clinicians, with historic control participants recruited from other Australian studies. Samples were either directly sequenced or had genotypes determined by imputation (for the Australian registry and historic control participants). Recruitment to the UKBB occurred between 2006 and 2010, and data analysis occurred from September 2017 to July 2018. Main Outcomes and Measures: The penetrance and odds ratio (OR) were estimated for the MYOC p.Gln368Ter variants in participants with glaucoma and OHT. Results: A total of 411 337 UKBB participants of white British ancestry (mean [SD] age, 56.6 [8.0] years) were included, plus 3071 Australian registry and 6750 historic control participants. In the UKBB, the minor allele frequency of the MYOC p.Gln368Ter variant was 1 in 786 individuals (0.13%). The odds ratio of p.Gln368Ter in patients with primary open-angle glaucoma (POAG) was 6.76 (95% CI, 4.05-11.29); glaucoma (POAG, self-reported glaucoma, and unspecified glaucoma), 4.40 (95% CI, 3.38-5.71); OHT, 3.56 (95% CI, 2.53-4.92); and OHT and glaucoma combined, 4.18 (95% CI, 3.05-5.67). The penetrance of the MYOC p.Gln368Ter variant was 7.6% in patients with glaucoma, 24.3% in patients with OHT, and 30.8% in patients with OHT and glaucoma combined. In the Australian registry studies, the odds of MYOC p.Gln368Ter variant were 12.16 (95% CI, 6.34-24.97) in patients with advanced glaucoma and 3.97 (95% CI, 1.55-9.75) in those with nonadvanced glaucoma; the penetrance of glaucoma was 56.1%, and penetrance in those considered to have glaucoma or be glaucoma suspects was 69.5%. Conclusions and Relevance: The MYOC p.Gln368Ter variant confers a very high-risk effect size for advanced glaucoma; the risk is lower in nonadvanced glaucoma and OHT. In the general population sample, approximately 50% of MYOC p.Gln368Ter carriers 65 years and older had glaucoma or OHT, with higher prevalence in the Australian registry studies.
Importance: The p.Gln368Ter (rs74315329) risk allele in the myocilin gene (MYOC) was initially reported to have high penetrance in glaucoma registry-based studies, but much lower estimates were recently obtained from population-based studies. We investigated this disparity using data from Australia and the United Kingdom. Objectives: To examine the penetrance and effect size of the MYOCp.Gln368Ter variant with glaucoma and ocular hypertension (OHT). Design, Setting, and Participants: This cross-sectional study within the UK Biobank (UKBB) included participants of white British ancestry. Glaucoma cases were defined by International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) diagnoses and self-reported questionnaires. Carriers of the MYOCp.Gln368Ter variant were identified using genotype imputation from arrays. In contrast, 2 Australian registry-based studies, the Australian and New Zealand Registry of Advanced Glaucoma and the Glaucoma Inheritance Study in Tasmania, ascertained glaucoma cases referred by eye care clinicians, with historic control participants recruited from other Australian studies. Samples were either directly sequenced or had genotypes determined by imputation (for the Australian registry and historic control participants). Recruitment to the UKBB occurred between 2006 and 2010, and data analysis occurred from September 2017 to July 2018. Main Outcomes and Measures: The penetrance and odds ratio (OR) were estimated for the MYOCp.Gln368Ter variants in participants with glaucoma and OHT. Results: A total of 411 337 UKBB participants of white British ancestry (mean [SD] age, 56.6 [8.0] years) were included, plus 3071 Australian registry and 6750 historic control participants. In the UKBB, the minor allele frequency of the MYOCp.Gln368Ter variant was 1 in 786 individuals (0.13%). The odds ratio of p.Gln368Ter in patients with primary open-angle glaucoma (POAG) was 6.76 (95% CI, 4.05-11.29); glaucoma (POAG, self-reported glaucoma, and unspecifiedglaucoma), 4.40 (95% CI, 3.38-5.71); OHT, 3.56 (95% CI, 2.53-4.92); and OHT and glaucoma combined, 4.18 (95% CI, 3.05-5.67). The penetrance of the MYOCp.Gln368Ter variant was 7.6% in patients with glaucoma, 24.3% in patients with OHT, and 30.8% in patients with OHT and glaucoma combined. In the Australian registry studies, the odds of MYOCp.Gln368Ter variant were 12.16 (95% CI, 6.34-24.97) in patients with advanced glaucoma and 3.97 (95% CI, 1.55-9.75) in those with nonadvanced glaucoma; the penetrance of glaucoma was 56.1%, and penetrance in those considered to have glaucoma or be glaucoma suspects was 69.5%. Conclusions and Relevance: The MYOCp.Gln368Ter variant confers a very high-risk effect size for advanced glaucoma; the risk is lower in nonadvanced glaucoma and OHT. In the general population sample, approximately 50% of MYOCp.Gln368Ter carriers 65 years and older had glaucoma or OHT, with higher prevalence in the Australian registry studies.
Authors: Rikkert van der Valk; Carroll A B Webers; Jan S A G Schouten; Maurice P Zeegers; Fred Hendrikse; Martin H Prins Journal: Ophthalmology Date: 2005-07 Impact factor: 12.079
Authors: Jost B Jonas; Tin Aung; Rupert R Bourne; Alain M Bron; Robert Ritch; Songhomitra Panda-Jonas Journal: Lancet Date: 2017-05-31 Impact factor: 79.321
Authors: Emmanuelle Souzeau; Ivan Goldberg; Paul R Healey; Richard A D Mills; John Landers; Stuart L Graham; John R B Grigg; Bronwyn Usher; Tania Straga; April Crawford; Robert J Casson; William H Morgan; Jonathan B Ruddle; Michael A Coote; Andrew White; James Stewart; Alex W Hewitt; David A Mackey; Kathryn P Burdon; Jamie E Craig Journal: Clin Exp Ophthalmol Date: 2012-08 Impact factor: 4.207
Authors: Dale R Nyholt; Siew-Kee Low; Carl A Anderson; Jodie N Painter; Satoko Uno; Andrew P Morris; Stuart MacGregor; Scott D Gordon; Anjali K Henders; Nicholas G Martin; John Attia; Elizabeth G Holliday; Mark McEvoy; Rodney J Scott; Stephen H Kennedy; Susan A Treloar; Stacey A Missmer; Sosuke Adachi; Kenichi Tanaka; Yusuke Nakamura; Krina T Zondervan; Hitoshi Zembutsu; Grant W Montgomery Journal: Nat Genet Date: 2012-10-28 Impact factor: 38.330
Authors: Pirro G Hysi; Ching-Yu Cheng; Henriët Springelkamp; Stuart Macgregor; Jessica N Cooke Bailey; Robert Wojciechowski; Veronique Vitart; Abhishek Nag; Alex W Hewitt; René Höhn; Cristina Venturini; Alireza Mirshahi; Wishal D Ramdas; Gudmar Thorleifsson; Eranga Vithana; Chiea-Chuen Khor; Arni B Stefansson; Jiemin Liao; Jonathan L Haines; Najaf Amin; Ya Xing Wang; Philipp S Wild; Ayse B Ozel; Jun Z Li; Brian W Fleck; Tanja Zeller; Sandra E Staffieri; Yik-Ying Teo; Gabriel Cuellar-Partida; Xiaoyan Luo; R Rand Allingham; Julia E Richards; Andrea Senft; Lennart C Karssen; Yingfeng Zheng; Céline Bellenguez; Liang Xu; Adriana I Iglesias; James F Wilson; Jae H Kang; Elisabeth M van Leeuwen; Vesteinn Jonsson; Unnur Thorsteinsdottir; Dominiek D G Despriet; Sarah Ennis; Sayoko E Moroi; Nicholas G Martin; Nomdo M Jansonius; Seyhan Yazar; E-Shyong Tai; Philippe Amouyel; James Kirwan; Leonieke M E van Koolwijk; Michael A Hauser; Fridbert Jonasson; Paul Leo; Stephanie J Loomis; Rhys Fogarty; Fernando Rivadeneira; Lisa Kearns; Karl J Lackner; Paulus T V M de Jong; Claire L Simpson; Craig E Pennell; Ben A Oostra; André G Uitterlinden; Seang-Mei Saw; Andrew J Lotery; Joan E Bailey-Wilson; Albert Hofman; Johannes R Vingerling; Cécilia Maubaret; Norbert Pfeiffer; Roger C W Wolfs; Hans G Lemij; Terri L Young; Louis R Pasquale; Cécile Delcourt; Timothy D Spector; Caroline C W Klaver; Kerrin S Small; Kathryn P Burdon; Kari Stefansson; Tien-Yin Wong; Ananth Viswanathan; David A Mackey; Jamie E Craig; Janey L Wiggs; Cornelia M van Duijn; Christopher J Hammond; Tin Aung Journal: Nat Genet Date: 2014-08-31 Impact factor: 38.330
Authors: Michelle P Y Chan; David C Broadway; Anthony P Khawaja; Jennifer L Y Yip; David F Garway-Heath; Jennifer M Burr; Robert Luben; Shabina Hayat; Nichola Dalzell; Kay-Tee Khaw; Paul J Foster Journal: BMJ Date: 2017-09-13
Authors: Nazlee Zebardast; Sayuri Sekimitsu; Jiali Wang; Tobias Elze; Puya Gharahkhani; Brian S Cole; Michael M Lin; Ayellet V Segrè; Janey L Wiggs Journal: Ophthalmology Date: 2021-03-10 Impact factor: 14.277
Authors: Sean Mullany; Henry Marshall; Santiago Diaz-Torres; Ella C Berry; Joshua M Schmidt; Daniel Thomson; Ayub Qassim; Minh-Son To; David Dimasi; Abraham Kuot; Lachlan S W Knight; Georgina Hollitt; Antonia Kolovos; Angela Schulz; Stewart Lake; Richard A Mills; Ashish Agar; Anna Galanopoulos; John Landers; Paul Mitchell; Paul R Healey; Stuart L Graham; Alex W Hewitt; Emmanuelle Souzeau; Mark M Hassall; Sonja Klebe; Stuart MacGregor; Puya Gharahkhani; Robert J Casson; Owen M Siggs; Jamie E Craig Journal: Ophthalmol Sci Date: 2022-04-19